Skip to main content
Ryan Sullivan, MD, Oncology, Boston, MA

RyanJSullivanMD

Oncology • Boston, MA

Physician

Join to view full profile

Dr. Sullivan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sullivan's full profile

Already have an account?

  • Office

    55 Fruit Street
    Boston, MA 02114
    Phone+1 617-724-4000

Summary

  • Dr. Ryan Sullivan is an oncologist based in Cambridge, MA, specializing in hematologic oncology and melanoma, including melanoma and cutaneous malignancies. He completed his medical education at Uconn School Of Medicine in 2001, followed by a residency in internal medicine at Mount Auburn Hospital and a fellowship in hematology and medical oncology at Beth Israel Deaconess Medical Center. Dr. Sullivan has contributed to several publications, focusing on melanoma and immunotherapy, and has been involved in various clinical trials exploring treatments for BRAF-mutant melanoma and other advanced cancers.

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Mount Auburn Hospital
    Mount Auburn HospitalResidency, Internal Medicine, 2001 - 2004
  • Uconn School Of Medicine
    Uconn School Of MedicineClass of 2001

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2004 - 2025
  • NH State Medical License
    NH State Medical License 2024 - 2024
  • ME State Medical License
    ME State Medical License 2020 - 2021
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
    Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
  • Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
    Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature

Lectures

  • Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing — Immunotherapy Sequencing... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

Authored Content

  • Forestalling BRAF-Inhibitor Resistance in a Shocking WayJuly 2018
  • Corrigendum to “Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study*” [Eur J Cancer 91 (2018) 116–124]March 2018
  • Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study☆February 2018

Press Mentions

  • Breakthrough Study Shows Promise for mRNA Cancer Vaccines
    Breakthrough Study Shows Promise for mRNA Cancer VaccinesApril 17th, 2023
  • In What Could Be a 'Big Shift' for Cancer Treatment, mRNA Vaccine Shows Promise Against Melanoma
    In What Could Be a 'Big Shift' for Cancer Treatment, mRNA Vaccine Shows Promise Against MelanomaApril 16th, 2023
  • Study Suggests Narrow Excision Margins Safe in Early Melanoma Resection
    Study Suggests Narrow Excision Margins Safe in Early Melanoma ResectionApril 14th, 2023
  • Join now to see all

Dr. Ryan Sullivan, Dr. Ryan Sullivan, MD, Dr. R Sullivan, Dr. Ryan J Sullivan